- Home
- SSYS vs XERS Comparison
SSYS vs XERS Comparison
Compare SSYS & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSYS
- XERS
- Stock Information
- Founded
- SSYS 1989
- XERS 2005
- Country
- SSYS United States
- XERS United States
- Employees
- SSYS N/A
- XERS N/A
- Industry
- SSYS Computer peripheral equipment
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- SSYS Technology
- XERS Health Care
- Exchange
- SSYS Nasdaq
- XERS Nasdaq
- Market Cap
- SSYS 438.2M
- XERS 444.0M
- IPO Year
- SSYS 1994
- XERS 2018
- Fundamental
- Price
- SSYS $7.49
- XERS $3.02
- Analyst Decision
- SSYS Strong Buy
- XERS Strong Buy
- Analyst Count
- SSYS 4
- XERS 3
- Target Price
- SSYS $10.75
- XERS $4.67
- AVG Volume (30 Days)
- SSYS 407.0K
- XERS 1.0M
- Earning Date
- SSYS 11-14-2024
- XERS 11-07-2024
- Dividend Yield
- SSYS N/A
- XERS N/A
- EPS Growth
- SSYS N/A
- XERS N/A
- EPS
- SSYS N/A
- XERS N/A
- Revenue
- SSYS $600,561,000.00
- XERS $181,413,000.00
- Revenue This Year
- SSYS N/A
- XERS $20.35
- Revenue Next Year
- SSYS $4.53
- XERS $16.14
- P/E Ratio
- SSYS N/A
- XERS N/A
- Revenue Growth
- SSYS N/A
- XERS 35.31
- 52 Week Low
- SSYS $6.05
- XERS $1.46
- 52 Week High
- SSYS $14.93
- XERS $3.26
- Technical
- Relative Strength Index (RSI)
- SSYS 49.63
- XERS 59.12
- Support Level
- SSYS $7.38
- XERS $2.97
- Resistance Level
- SSYS $7.77
- XERS $3.12
- Average True Range (ATR)
- SSYS 0.23
- XERS 0.12
- MACD
- SSYS -0.01
- XERS 0.01
- Stochastic Oscillator
- SSYS 41.25
- XERS 74.36
About SSYS Stratasys Ltd. (Israel)
Stratasys Ltd is a polymer-based 3D printing solution, which provides a product life cycle, with multiple technologies and complete solutions for superior application fit, across industrial, healthcare, and consumer fields. It focuses, in particular, on polymer 3D printing solutions that address the fastest-growing manufacturing solutions viewed as the potential growth opportunity in the 3D printing industry. Its printers include FDM, PolyJet, Stereolithography, P3, and SAF. Its software is GrabCAD Software, Connectivity, Digital Anatomy Creator, and OpenAM Software. It generates revenue through 3D printing systems, related services, and consumables and by providing additive manufacturing solutions.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.